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Abstract
Background: Sjögren’s syndrome (SS) has been associated with bronchial hyperresponsiveness and asthma;
however, no population-based cohort study has been performed. We evaluated the risk of asthma in patients
with primary SS in a nationwide population.
Methods: We conducted a retrospective cohort study using data from the National Health Insurance Research
Database in Taiwan. The primary SS group included 4725 adult patients diagnosed between 2000 and 2006. Each
patient was frequency-matched with four people without SS by sex, age and year of diagnosis. The occurrence and
hazard ratio (HR) of asthma was monitored by the end of 2011.
Results: The overall incidence density of asthma was 1.62-fold higher in the primary SS group than in the non-SS
group (9.86 vs. 6.10 per 1000 person-years), with a multivariable Cox proportional hazards model measured adjusted
HR of 1.38 [95% confidence interval (CI) = 1.21–1.58]. Stratified analyses by sex, age group, and presence of
comorbidity revealed that asthma incidences were all higher in the primary SS group than in the non-SS group,
and the relative HRs of asthma associated with primary SS were significant in all subgroups.
Conclusion: Patients with primary SS are associated with an increased risk of developing asthma. We should pay
more attention to this group of individuals and provide them with appropriate support.
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Background
Sjögren’s syndrome (SS) is an autoimmune disease char-
acterized by hypofunction of the lacrimal and salivary
glands; however, the effects of SS are not limited to the
eyes and mouth. SS is also featured by lymphocytic
infiltration of exocrine glands. SS can present as an inde-
pendent disorder itself (primary SS) or as a result of
other autoimmune diseases, such as systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), sys-
temic sclerosis, or primary biliary cirrhosis (secondary
SS) [1, 2]. Approximately 90% of primary SS cases are
females and more prevalent in Caucasian women, with
the mean onset age of 40 − 59 [2]. With the incidence of
3.9–5.3 per 100,000 [3, 4], the etiology of SS remains
largely unknown. The combination of genetic, environ-
mental, and hormonal factors may trigger the disorder
[5]. Patients with SS may develop pulmonary manifesta-
tions such as airway disease and interstitial lung disease
and follicular bronchiolitis is the most common histo-
logic finding. Patients with significant pulmonary in-
volvement could be at a 4-fold increased risk of death
[6]. Therefore, recognition of these conditions is critical
in caring for SS patients.
Asthma is a common respiratory disorder character-
ized by symptoms of wheezing, shortness of breath,
chest tightness and cough. The occurrence, intensity,
and frequency of these symptoms vary over time, and
are associated with variable expiratory airflow, airway
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wall thickening, and mucus development [7]. Adult- and
childhood- onset asthma are quite different; the former
is generally non-allergic with severer symptoms and
rapid decline in pulmonary function [8]. Pollutants and
irritants exposure, upper airway diseases, respiratory in-
fections, female sex hormones, medications, obesity, and
stressful life events have been associated with the adult-
onset asthma [9].
Previous studies have described SS and the risk of re-
spiratory disorders, including bronchial hyperresponsive-
ness (BHR) and asthma [10–16]. Fairfax et al. reported
that 2 out of 17 (11.8%) patients with SS were also co-
morbid with asthma [15]. In a large scale case-control
study, Kang et al. reported that the prevalence of asthma
was greater in the SS cases than in controls (5.1 vs.
3.4%), with an adjusted odd ratio (OR) of 1.54 [95%
confidence interval (CI) = 1.22–1.93] [16]. However, the
risk of asthma in patients with primary SS compared to
the general population is largely unknown.
The National Health Insurance Research Database
(NHIRD) of Taiwan is a nationwide database with cohort
data including 23 million people. These reliable data
have been used for various studies, including several on
SS and asthma [17–20]. The hypothesis of this study is
that primary SS may increase the likelihood of subse-
quent diagnosis of asthma. This study was to investigate
the risk of asthma in patients with primary SS and com-
pare it with the general population.
Methods
Data sources
The National Health Insurance (NHI) is a universal
insurance program, which was reformed from 13 insur-
ance systems in 1995. This insurance project has
provided comprehensive coverage for >99% of popula-
tion since 1996. For the present study, we used the
Registry of Catastrophic Illnesses Patient Database
(RCIPD) and Longitudinal Health Insurance Database
2000 (LHID2000), which are parts of the NHIRD. The
RCIPD contains health claims data for people with 30
major diseases, such as cancer, end-stage renal disease,
chronic mental illness, and several autoimmune diseases,
which are diseases requiring long-term care and are
granted with co-pay exemption. The LHID2000 includes
longitudinal data on medical claims for 1,000,000 indi-
viduals randomly sampled from the 2000 Registry of
Beneficiaries. Both RCIPD and LHID2000 contain infor-
mation on demographic data, clinical visits, prescription
details, and diagnostic codes based on the International
Classification of Diseases, Ninth revision, Clinical Modi-
fication (ICD-9-CM). All personal identifications in the
data file were encrypted for privacy protection before be-
ing released for research; therefore, written informed
consent from the participants involved was unavailable
and unnecessary. This study was approved by the Re-
search Ethic Committee of China Medical University
and Hospital (CMUH-104-REC2-115).
Study population
From the data sets of RCIPD and LHID2000, we estab-
lished two study cohorts for the population-based retro-
spective cohort study: primary SS cohort and non-SS
cohort. Using the data file of RCIPD, adult patients with
SS (ICD9-CM code 710.2) newly diagnosed during
2000–2006 were identified as the primary SS cohort.
The date that the patient was approved with catastrophic
illness certificate was designated as the index date. We
excluded patients with secondary SS or a previous diag-
nosis of asthma (ICD-9-CM code 493). A secondary SS
diagnosis was defined as a diagnosis of SS associated
with SLE (ICD-9-CM code 710.0), RA (ICD-9-CM code
714), systemic sclerosis (ICD-9-CM code 710.1), or pri-
mary biliary cirrhosis (ICD-9-CM code 571.6) [17]. For
each patient with primary SS, four insured individuals
without SS or asthma were selected from LHID2000 as
the non-SS cohort and were frequency-matched based
on sex, age (every 5-years span), and year of the index
date. The American-European Consensus Criteria was
most commonly applied for the diagnosis of SS. Accord-
ing to the criteria, the diagnosis of SS can be met by ful-
filling four out of six items, including ocular symptoms,
oral symptoms, ocular signs, oral signs, evidence of
histopathology, and presence of autoantibodies [21].
Covariates and outcome
Demographic factors including sex, age (age groups:
20–39, 40–59, and ≥60 years), and medical histories
(before the index date) of allergic rhinitis (ICD-9-CM
code 477), chronic sinusitis (ICD-9-CM code 473),
atopic dermatitis (ICD-9-CM code 691.8), chronic ob-
structive pulmonary disease (COPD; ICD-9-CM code
496), gastroesophageal reflux disease (GERD; ICD-9-CM
codes 530.11 and 530.81), and obesity (ICD-9-CM code
278) were identified as comorbidities.
The primary outcome measure was asthma. Only pa-
tients with the diagnosis of asthma (ICD-9-CM code
493) at least twice within 1 year and prescription of
treatment for asthma were identified as asthma cases to
increase the validity and accuracy. The time of follow-up
began with the index date and ended with a new diagno-
sis of asthma, death, withdrawal from the insurance pro-
gram, or the end of follow-up on December 31, 2011.
Statistical analysis
Distributions of sex, age, and comorbidity were com-
pared. The Pearson’s Chi-square test and Student’s t-test
were used to determine the differences in categorical
and continuous variables between the primary SS and
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non-SS groups. The incidence density of asthma was cal-
culated by dividing the incident number of asthma by
the follow-up person-years. We estimated the cumula-
tive incidence of asthma by using the Kaplan-Meier
method for the primary SS and non-SS groups and
assessed their differences using the log-rank test. We
used Cox proportional hazards regression to estimate
the hazard ratios (HRs) and 95% CIs of asthma to evalu-
ate the independent effect of primary SS stratified by
sex, age, and comorbidity. All statistical analyses were
performed using SAS 9.4 (SAS System for Windows,
SAS Institute, Cary, NC, USA). Results of comparisons
using a two-tailed p-value of <0.05 were considered sta-
tistically significant.
Results
This study included 4725 patients with primary SS and
18900 individuals without SS that displayed similar dis-
tributions of sex and age (Table 1). The mean age of the
primary SS group was 53.1 (SD = 14.0) years, and 87.3%
of patients were women. Prevalence rates of allergic
rhinitis, chronic sinusitis, atopic dermatitis, COPD, and
GERD were all greater in patients with SS than individ-
uals without SS (p < 0.001 for all).
Figure 1 shows that the cumulative incidence of
asthma was 3.2% higher in the primary SS group than
in the non-SS group (9.0 vs. 5.8%, p < 0.001) after 12-
year follow-up. During an average follow-up of
7.31 years, the incidence density of asthma was greater
in the primary SS group than in the non-SS group, 9.86
vs. 6.10 per 1000 person-years (Table 2). The multivari-
able Cox method estimated adjusted HR of asthma was
1.38 (95% CI = 1.21–1.58) for the primary SS group com-
pared with non-SS group after controlling for sex, age,
and comorbidities. The adjusted HRs were 1.41 in the
40–59 years age group (95% CI = 1.16–1.70) and 2.65 in
the ≥60 years age group (95% CI = 2.19–3.22), compared
with those aged less than 40 years. Compared with indi-
viduals free of COPD, those with COPD had an adjusted
HR of 2.52 (95% CI = 1.91–3.33) for developing asthma.
On the other hand, adjusted HRs were 1.76 (95% CI =
1.51–2.06) for individuals with allergic rhinitis, 1.71
(95% CI = 1.31–2.22) for individuals with chronic sinus-
itis, and 2.05 (95% CI = 1.10–3.82) for individuals with
obesity.
Table 3 shows incident asthma for both study cohorts
by sex, age and comorbidity status. The primary SS
group to the non-SS group adjusted HR was significant
for women (1.39, 95% CI = 1.21–1.60). Age stratification
demonstrated that incidence of asthma increased with
age in both cohorts. The primary SS to non-SS group
hazard ratio was greater for younger individuals. For in-
dividuals without comorbidity, those in the primary SS
group had an adjusted HR of 1.47 (95% CI = 1.25–1.72)
compared with those in the non-SS group.
Discussion
To the best of our knowledge, this is the first nationwide
population-based retrospective cohort study to investi-
gate the risk of asthma in patients with primary SS,
comparing with general population. Results revealed that
Table 1 Demographic factors and comorbidities of study





Variable n % n % p-value
Sex >0.99
Women 16508 87.3 4127 87.3
Men 2392 12.7 598 12.7
Age, years >0.99
20 − 39 3524 18.7 881 18.7
40 − 59 9532 50.4 2383 50.4
≥ 60 5844 30.9 1461 30.9
Means (SD) 52.8 (14.3) 53.1 (14.0) 0.20
Comorbidity
Allergic rhinitis 1566 8.29 997 21.1 <0.001
Chronic sinusitis 281 1.49 262 5.54 <0.001
Atopic dermatitis 259 1.37 111 2.35 <0.001
COPD 221 1.17 132 2.79 <0.001
GERD 77 0.41 95 2.01 <0.001
Obesity 85 0.45 20 0.42 0.90
COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux
disease, SD standard deviation, SS Sjögren’s syndrome
Fig. 1 Cumulative incidence of asthma in primary SS group and
non-SS group
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patients with primary SS had an increased risk of asthma
compared to those without SS. Stratified analyses by sex,
age group, and presence of comorbidity also showed that
the incidence rates of asthma were consistently higher in
primary SS patients than in the comparison group, and
the relative HRs of asthma associated with primary SS
were significant for all subgroups. However, there were re-
duced significance levels in calculating adjusted HRs for
some subgroups including males, those aged >60 years,
and those with any comorbidity. The possible explanation
for this may be that the case numbers were reduced in
these subgroups, which in turn influenced the statistical
power.
Asthma is a heterogeneous disease associated with dif-
ferent underlying disease processes and pathophysiol-
ogies. Recently, cluster analysis have classified asthma
phenotypes by clusters of demographic, clinical, or
pathophysiological characteristics [7]. A large number of
studies have documented that adults with asthma may
not associate with allergies, and the cellular profile of
their airways may be neutrophilic, eosinophilic, or other
types. These patients are classified as having non-allergic
or adult-onset (late-onset) asthma, and they often re-
spond less well to inhaled corticosteroid treatment [7].
Primary SS patients with BHR have characteristics simi-
lar to those with non-allergic or adult-onset asthma.
Papiris et al. have reported that CD4 positive T-
lymphocytes in the bronchial mucosa are increased out-
side of the bronchial glands in patients with SS, support-
ing the fact that SS involves extra-glandular tissues in
the airways [22]. Amin et al. found that number of neu-
trophils, mast cells and T lymphocytes in the airways
were higher in patients with primary SS than in healthy
controls, while the number of eosinophils was similar in
SS patients and controls [23]. Stalenheim et al. reported
that inhaled budesonide was less effective for alleviating
BHR in patients with SS [24]. In addition, Amin et al.
have observed a lowered degree of epithelial integrity,
but thicker tenascin and laminin layers in primary SS
patients than in controls [23]. They concluded that
structural changes in the airways relating to BHR were
similar in SS patients and asthma patients [23]. There-
fore, it is reasonable to include primary SS patients with
BHR and related respiratory symptoms into a certain
phenotype of asthma, which met the clinical diagnostic
criteria.
Tobacco smoking has been considered as a potential
confounding factor in the present study because the
NHIRD does not contain data on personal smoking
habits. One study has reported a weak association be-
tween cigarette smoking and the development of pri-
mary SS [25], while most studies reported no significant
difference in smoking between primary SS patients and
controls [26–28]. The case-control study on cardiovas-
cular diseases even found significantly fewer smokers in
the SS patient groups [29, 30]. Therefore, patients with
SS may not have a significantly higher smoking rate than
those without SS [18].
In the present study, we were able to observe a “real
world” scenario using the claims data, in which primary
SS, asthma, and comorbidities were directly diagnosed
during medical consultations. In terms of the disease
definition and patient registry, SS is categorized as a
Table 2 Cox model measure hazard ratios and 95% confidence
intervals of asthma associated with primary Sjögren’s syndrome
and covariates
Variables Events IR HR (95% CI)
Univariate Multivariatea
Primary SS
No 844 6.10 1.00 1.00
Yes 337 9.86 1.62 (1.42 − 1.83)*** 1.38 (1.21 − 1.58)***
Sex
Women 1007 6.62 1.00 1.00
Men 174 8.45 1.26 (1.07 − 1.48)** 0.90 (0.76 − 1.06)
Age, years
20 − 39 134 3.95 1.00 1.00
40 − 59 504 5.61 1.41 (1.17 − 1.71)*** 1.41 (1.16 − 1.70)***
≥ 60 543 11.1 2.74 (2.27 − 3.31)*** 2.65 (2.19 − 3.22)**
Comorbidity
Allergic rhinitis
No 952 6.13 1.00 1.00
Yes 229 13.1 2.08 (1.80 − 2.41)*** 1.76 (1.51 − 2.06)***
Chronic sinusitis
No 1116 6.61 1.00 1.00
Yes 65 17.5 2.58 (2.01 − 3.32)*** 1.71 (1.31 − 2.22)***
Atopic dermatitis
No 1153 6.77 1.00 1.00
Yes 28 11.8 1.67 (1.15 − 2.43)** 1.39 (0.95 − 2.02)
COPD
No 1123 6.58 1.00 1.00
Yes 58 29.8 4.30 (3.30 − 5.60)*** 2.52 (1.91 − 3.33)***
GERD
No 1167 6.80 1.00 1.00
Yes 14 15.2 2.03 (1.20 − 3.41)** 1.28 (0.75 − 2.17)
Obesity
No 1171 6.81 1.00 1.00
Yes 10 14.1 2.02 (1.09 − 3.77)* 2.05 (1.10 − 3.82)*
CI confidence interval, COPD chronic obstructive pulmonary disease, GERD
gastroesophageal reflux disease, HR hazard ratio, IR incidence density rate per
1000 person-years, SS Sjögren’s syndrome
aModel was adjusted for sex, age and comorbidity in Cox proportional hazards
regression
*p <0.05, **p <0.01, ***p <0.001
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“catastrophic illness” and patients diagnosed with SS are
entitled to receive the “catastrophic illness certification”
issued by the government. Experts specializing in the
disease make critical evaluation of claims data, including
serological, and/or pathological reports with reference to
the American-European Consensus Criteria [21]. The
diagnosis of asthma depends on a target history and re-
quires comprehensive evidence of variable expiratory
airflow limitations. We typically follow the Global Initia-
tive for Asthma (GINA) guideline to arrive at an asthma
diagnosis [7]. The insurance authority has established a
committee to evaluate the claims data to prevent errors
and violations. In addition, we only selected those diag-
noses (asthma and comorbidities) that appeared at least
twice within 1 year to increase the validity and accuracy
of the diagnosis.
The universal coverage of the NHI project reduces
barriers to health care access for all insured population,
regardless of socioeconomic status [31]. In an earlier
case-control study evaluating comorbidities for patients
with primary SS, Kang et al. reported an odds ratio of
1.54 for asthma risk in primary SS patients, which is
similar to our findings [16]. We suggest further evalu-
ation of the differences in medications prescribed for
asthma patients with primary SS compared to those
without SS to better understand the current and com-
mon medical treatments for this population. In addition,
future studies should evaluate the treatment outcomes
such as acute exacerbations, admissions, intensive care,
or mortality due to asthma in patients with primary SS.
The strength of this study comes from using the
longitudinal population-based data to evaluate the
asthma risk in primary SS patients. It is generally
costly to conduct a population-based prospective co-
hort study. A retrospective cohort study based on in-
surance or registry data is an economically suitable
alternative to evaluate this relationship, full compli-
ance with the requirements of a follow-up study.
However, several limitations of the study must be
considered when interpreting the present findings.
First, the NHIRD does not provide detailed informa-
tion on potential confounding factors for this study,
such as environmental factors, personal habits, diet
preference, and family history. Since the crucial infor-
mation is missing, it is difficult to judge whether we
have used the most suitable comparison individuals.
In addition, relevant clinical variables, such as image
reports, histopathology results, serum laboratory data,
pulmonary function tests, and symptom frequency in
patients were also unavailable. We were unable to
evaluate whether there is dose-response relationship
between asthmatic risk and symptom frequency in SS
patients.
Conclusion
Patients with primary SS are associated with a higher
risk of developing asthma than those without SS. The
association between primary SS and allergic or non-
allergic asthma needs further investigation. In any case,
we should pay more attention to patients with primary
SS and provide them with appropriate support.
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